| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| GILD - Guild Esports Plc | BUY | 1,403 @ USD 152.5 | USD 213,958 | The ETF bought 1403 new shares of GILD (Guild Esports Plc). The shares were bought for an average price of 152.5 compared to the previous average buy price of 119.063. This is 28.1% higher than average price of previous purchases of GILD. |
| AMGN - Amgen Inc | BUY | 511 @ USD 384.32 | USD 196,388 | The ETF bought 511 new shares of AMGN (Amgen Inc). The shares were bought for an average price of 384.32 compared to the previous average buy price of 308.388. This is 24.6% higher than average price of previous purchases of AMGN. |
| VRTX - Vertex Pharmaceuticals Inc | BUY | 407 @ USD 477.92 | USD 194,513 | The ETF bought 407 new shares of VRTX (Vertex Pharmaceuticals Inc). The shares were bought for an average price of 477.92 compared to the previous average buy price of 444.938. This is 7.4% higher than average price of previous purchases of VRTX. |
| REGN - Regeneron Pharmaceuticals Inc | BUY | 168 @ USD 785.51 | USD 131,966 | The ETF bought 168 new shares of REGN (Regeneron Pharmaceuticals Inc). The shares were bought for an average price of 785.51 compared to the previous average buy price of 662.547. This is 18.6% higher than average price of previous purchases of REGN. |
| ALNY - Alnylam Pharmaceuticals Inc | BUY | 215 @ USD 328.16 | USD 70,554 | The ETF bought 215 new shares of ALNY (Alnylam Pharmaceuticals Inc). The shares were bought for an average price of 328.16 compared to the previous average buy price of 384.598. This is -14.7% lower than average price of previous purchases of ALNY. |
| INSM - Insmed Inc | BUY | 346 @ USD 149.86 | USD 51,852 | The ETF bought 346 new shares of INSM (Insmed Inc). The shares were bought for an average price of 149.86 compared to the previous average buy price of 145.997. This is 2.6% higher than average price of previous purchases of INSM. |
| BIIB - Biogen Inc | BUY | 238 @ USD 201.18 | USD 47,881 | The ETF bought 238 new shares of BIIB (Biogen Inc). The shares were bought for an average price of 201.18 compared to the previous average buy price of 152.925. This is 31.6% higher than average price of previous purchases of BIIB. |
| ARGX - argenx NV ADR | BUY | 47 @ USD 811.45 | USD 38,138 | The ETF bought 47 new shares of ARGX (argenx NV ADR). The shares were bought for an average price of 811.45 compared to the previous average buy price of 732.556. This is 10.8% higher than average price of previous purchases of ARGX. |
| INCY - Incyte Corporation | BUY | 319 @ USD 108.39 | USD 34,576 | The ETF bought 319 new shares of INCY (Incyte Corporation). The shares were bought for an average price of 108.39 compared to the previous average buy price of 85.1547. This is 27.3% higher than average price of previous purchases of INCY. |
| UTHR - United Therapeutics Corporation | BUY | 70 @ USD 485.36 | USD 33,975 | The ETF bought 70 new shares of UTHR (United Therapeutics Corporation). The shares were bought for an average price of 485.36 compared to the previous average buy price of 395.619. This is 22.7% higher than average price of previous purchases of UTHR. |
| RPRX - Royalty Pharma Plc | BUY | 694 @ USD 44.65 | USD 30,987 | The ETF bought 694 new shares of RPRX (Royalty Pharma Plc). The shares were bought for an average price of 44.65 compared to the previous average buy price of 37.2148. This is 20.0% higher than average price of previous purchases of RPRX. |
| RVMD - Revolution Medicines Inc | BUY | 314 @ USD 97.49 | USD 30,612 | The ETF bought 314 new shares of RVMD (Revolution Medicines Inc). The shares were bought for an average price of 97.49 compared to the previous average buy price of 59.2668. This is 64.5% higher than average price of previous purchases of RVMD. |
| ILMN - Illumina Inc | BUY | 248 @ USD 119.72 | USD 29,691 | The ETF bought 248 new shares of ILMN (Illumina Inc). The shares were bought for an average price of 119.72 compared to the previous average buy price of 111.24. This is 7.6% higher than average price of previous purchases of ILMN. |
| ROIV - Roivant Sciences Ltd | BUY | 1,129 @ USD 25.82 | USD 29,151 | The ETF bought 1129 new shares of ROIV (Roivant Sciences Ltd). The shares were bought for an average price of 25.82 compared to the previous average buy price of 16.4881. This is 56.6% higher than average price of previous purchases of ROIV. |
| VTRS - Viatris Inc | BUY | 1,870 @ USD 14.58 | USD 27,265 | The ETF bought 1870 new shares of VTRS (Viatris Inc). The shares were bought for an average price of 14.58 compared to the previous average buy price of 10.3728. This is 40.6% higher than average price of previous purchases of VTRS. |
| MRNA - Moderna Inc | BUY | 634 @ USD 41.01 | USD 26,000 | The ETF bought 634 new shares of MRNA (Moderna Inc). The shares were bought for an average price of 41.01 compared to the previous average buy price of 29.8637. This is 37.3% higher than average price of previous purchases of MRNA. |
| MEDP - Medpace Holdings Inc | BUY | 46 @ USD 542.04 | USD 24,934 | The ETF bought 46 new shares of MEDP (Medpace Holdings Inc). The shares were bought for an average price of 542.04 compared to the previous average buy price of 470.006. This is 15.3% higher than average price of previous purchases of MEDP. |
| NBIX - Neurocrine Biosciences Inc | BUY | 162 @ USD 141.2 | USD 22,874 | The ETF bought 162 new shares of NBIX (Neurocrine Biosciences Inc). The shares were bought for an average price of 141.2 compared to the previous average buy price of 135.563. This is 4.2% higher than average price of previous purchases of NBIX. |
| IONS - Ionis Pharmaceuticals Inc | BUY | 263 @ USD 86.5 | USD 22,750 | The ETF bought 263 new shares of IONS (Ionis Pharmaceuticals Inc). The shares were bought for an average price of 86.5 compared to the previous average buy price of 60.3502. This is 43.3% higher than average price of previous purchases of IONS. |
| ASND - Ascendis Pharma AS | BUY | 100 @ USD 222.15 | USD 22,215 | The ETF bought 100 new shares of ASND (Ascendis Pharma AS). The shares were bought for an average price of 222.15 compared to the previous average buy price of 190.467. This is 16.6% higher than average price of previous purchases of ASND. |
| GH - Guardant Health Inc | BUY | 210 @ USD 101.85 | USD 21,389 | The ETF bought 210 new shares of GH (Guardant Health Inc). The shares were bought for an average price of 101.85 compared to the previous average buy price of 75.4303. This is 35.0% higher than average price of previous purchases of GH. |
| BBIO - BridgeBio Pharma Inc | BUY | 313 @ USD 68.05 | USD 21,300 | The ETF bought 313 new shares of BBIO (BridgeBio Pharma Inc). The shares were bought for an average price of 68.05 compared to the previous average buy price of 55.8903. This is 21.8% higher than average price of previous purchases of BBIO. |
| SNY - Sanofi ADR | BUY | 430 @ USD 47.83 | USD 20,567 | The ETF bought 430 new shares of SNY (Sanofi ADR). The shares were bought for an average price of 47.83 compared to the previous average buy price of 49.4733. This is -3.3% lower than average price of previous purchases of SNY. |
| EXEL - Exelixis Inc | BUY | 435 @ USD 43.9 | USD 19,097 | The ETF bought 435 new shares of EXEL (Exelixis Inc). The shares were bought for an average price of 43.9 compared to the previous average buy price of 42.073. This is 4.3% higher than average price of previous purchases of EXEL. |
| BMRN - Biomarin Pharmaceutical Inc | BUY | 312 @ USD 58.13 | USD 18,137 | The ETF bought 312 new shares of BMRN (Biomarin Pharmaceutical Inc). The shares were bought for an average price of 58.13 compared to the previous average buy price of 56.8952. This is 2.2% higher than average price of previous purchases of BMRN. |
| SMMT - Summit Therapeutics PLC | BUY | 1,209 @ USD 14.99 | USD 18,123 | The ETF bought 1209 new shares of SMMT (Summit Therapeutics PLC). The shares were bought for an average price of 14.99 compared to the previous average buy price of 19.8511. This is -24.5% lower than average price of previous purchases of SMMT. |
| RNA - Avidity Biosciences Inc | BUY | 245 @ USD 72.9 | USD 17,861 | The ETF bought 245 new shares of RNA (Avidity Biosciences Inc). The shares were bought for an average price of 72.9 compared to the previous average buy price of 54.1834. This is 34.5% higher than average price of previous purchases of RNA. |
| MDGL - Madrigal Pharmaceuticals Inc | BUY | 37 @ USD 477.6 | USD 17,671 | The ETF bought 37 new shares of MDGL (Madrigal Pharmaceuticals Inc). The shares were bought for an average price of 477.6 compared to the previous average buy price of 427.841. This is 11.6% higher than average price of previous purchases of MDGL. |
| BNTX - BioNTech SE | BUY | 164 @ USD 106.62 | USD 17,486 | The ETF bought 164 new shares of BNTX (BioNTech SE). The shares were bought for an average price of 106.62 compared to the previous average buy price of 103.622. This is 2.9% higher than average price of previous purchases of BNTX. |
| JAZZ - Jazz Pharmaceuticals PLC | BUY | 99 @ USD 165.5 | USD 16,385 | The ETF bought 99 new shares of JAZZ (Jazz Pharmaceuticals PLC). The shares were bought for an average price of 165.5 compared to the previous average buy price of 140.528. This is 17.8% higher than average price of previous purchases of JAZZ. |
| HALO - Halozyme Therapeutics Inc | BUY | 191 @ USD 81.23 | USD 15,515 | The ETF bought 191 new shares of HALO (Halozyme Therapeutics Inc). The shares were bought for an average price of 81.23 compared to the previous average buy price of 63.156. This is 28.6% higher than average price of previous purchases of HALO. |
| AXSM - Axsome Therapeutics Inc | BUY | 82 @ USD 182.55 | USD 14,969 | The ETF bought 82 new shares of AXSM (Axsome Therapeutics Inc). The shares were bought for an average price of 182.55 compared to the previous average buy price of 131.768. This is 38.5% higher than average price of previous purchases of AXSM. |
| ARWR - Arrowhead Pharmaceuticals Inc | BUY | 221 @ USD 64.52 | USD 14,259 | The ETF bought 221 new shares of ARWR (Arrowhead Pharmaceuticals Inc). The shares were bought for an average price of 64.52 compared to the previous average buy price of 35.098. This is 83.8% higher than average price of previous purchases of ARWR. |
| PRAX - Praxis Precision Medicines Inc | BUY | 41 @ USD 319.57 | USD 13,102 | The ETF bought 41 new shares of PRAX (Praxis Precision Medicines Inc). The shares were bought for an average price of 319.57 compared to the previous average buy price of 150.741. This is 112.0% higher than average price of previous purchases of PRAX. |
| KRYS - Krystal Biotech Inc | BUY | 47 @ USD 272.74 | USD 12,819 | The ETF bought 47 new shares of KRYS (Krystal Biotech Inc). The shares were bought for an average price of 272.74 compared to the previous average buy price of 192.86. This is 41.4% higher than average price of previous purchases of KRYS. |
| CYTK - Cytokinetics Inc | BUY | 199 @ USD 62.34 | USD 12,406 | The ETF bought 199 new shares of CYTK (Cytokinetics Inc). The shares were bought for an average price of 62.34 compared to the previous average buy price of 51.3354. This is 21.4% higher than average price of previous purchases of CYTK. |
| NUVL - Nuvalent Inc | BUY | 117 @ USD 103.59 | USD 12,120 | The ETF bought 117 new shares of NUVL (Nuvalent Inc). The shares were bought for an average price of 103.59 compared to the previous average buy price of 91.4401. This is 13.3% higher than average price of previous purchases of NUVL. |
| PCVX - Vaxcyte Inc | BUY | 213 @ USD 56.15 | USD 11,960 | The ETF bought 213 new shares of PCVX (Vaxcyte Inc). The shares were bought for an average price of 56.15 compared to the previous average buy price of 45.6413. This is 23.0% higher than average price of previous purchases of PCVX. |
| RYTM - Rhythm Pharmaceuticals Inc | BUY | 108 @ USD 103.61 | USD 11,190 | The ETF bought 108 new shares of RYTM (Rhythm Pharmaceuticals Inc). The shares were bought for an average price of 103.61 compared to the previous average buy price of 86.7098. This is 19.5% higher than average price of previous purchases of RYTM. |
| PTCT - PTC Therapeutics Inc | BUY | 130 @ USD 74.68 | USD 9,708 | The ETF bought 130 new shares of PTCT (PTC Therapeutics Inc). The shares were bought for an average price of 74.68 compared to the previous average buy price of 63.3651. This is 17.9% higher than average price of previous purchases of PTCT. |
| IBRX - Immunitybio Inc | BUY | 1,599 @ USD 6.05 | USD 9,674 | The ETF bought 1599 new shares of IBRX (Immunitybio Inc). The shares were bought for an average price of 6.05 compared to the previous average buy price of 2.91362. This is 107.6% higher than average price of previous purchases of IBRX. |
| ALKS - Alkermes Plc | BUY | 268 @ USD 34.91 | USD 9,356 | The ETF bought 268 new shares of ALKS (Alkermes Plc). The shares were bought for an average price of 34.91 compared to the previous average buy price of 30.2568. This is 15.4% higher than average price of previous purchases of ALKS. |
| KYMR - Kymera Therapeutics Inc | BUY | 117 @ USD 79.59 | USD 9,312 | The ETF bought 117 new shares of KYMR (Kymera Therapeutics Inc). The shares were bought for an average price of 79.59 compared to the previous average buy price of 55.6435. This is 43.0% higher than average price of previous purchases of KYMR. |
| COGT - Cogent Biosciences Inc | BUY | 249 @ USD 37.08 | USD 9,233 | The ETF bought 249 new shares of COGT (Cogent Biosciences Inc). The shares were bought for an average price of 37.08 compared to the previous average buy price of 22.9004. This is 61.9% higher than average price of previous purchases of COGT. |
| PTGX - Protagonist Therapeutics Inc | BUY | 102 @ USD 84.49 | USD 8,618 | The ETF bought 102 new shares of PTGX (Protagonist Therapeutics Inc). The shares were bought for an average price of 84.49 compared to the previous average buy price of 67.6242. This is 24.9% higher than average price of previous purchases of PTGX. |
| MIRM - Mirum Pharmaceuticals Inc | BUY | 83 @ USD 100.47 | USD 8,339 | The ETF bought 83 new shares of MIRM (Mirum Pharmaceuticals Inc). The shares were bought for an average price of 100.47 compared to the previous average buy price of 64.1901. This is 56.5% higher than average price of previous purchases of MIRM. |
| GPCR - Structure Therapeutics Inc. American Depositary Shares | BUY | 108 @ USD 74.92 | USD 8,091 | The ETF bought 108 new shares of GPCR (Structure Therapeutics Inc. American Depositary Shares). The shares were bought for an average price of 74.92 compared to the previous average buy price of 39.0299. This is 92.0% higher than average price of previous purchases of GPCR. |
| SRRK - Scholar Rock Holding Corp | BUY | 166 @ USD 47.62 | USD 7,905 | The ETF bought 166 new shares of SRRK (Scholar Rock Holding Corp). The shares were bought for an average price of 47.62 compared to the previous average buy price of 37.923. This is 25.6% higher than average price of previous purchases of SRRK. |
| IMVT - Immunovant Inc | BUY | 285 @ USD 27.05 | USD 7,709 | The ETF bought 285 new shares of IMVT (Immunovant Inc). The shares were bought for an average price of 27.05 compared to the previous average buy price of 20.1482. This is 34.3% higher than average price of previous purchases of IMVT. |
| CRSP - Crispr Therapeutics AG | BUY | 155 @ USD 48.74 | USD 7,555 | The ETF bought 155 new shares of CRSP (Crispr Therapeutics AG). The shares were bought for an average price of 48.74 compared to the previous average buy price of 53.3532. This is -8.6% lower than average price of previous purchases of CRSP. |
| AMRX - Amneal Pharmaceuticals, Inc. Class A Common Stock | BUY | 510 @ USD 14.52 | USD 7,405 | The ETF bought 510 new shares of AMRX (Amneal Pharmaceuticals, Inc. Class A Common Stock). The shares were bought for an average price of 14.52 compared to the previous average buy price of 10.2141. This is 42.2% higher than average price of previous purchases of AMRX. |
| FOLD - Amicus Therapeutics Inc | BUY | 501 @ USD 14.3 | USD 7,164 | The ETF bought 501 new shares of FOLD (Amicus Therapeutics Inc). The shares were bought for an average price of 14.3 compared to the previous average buy price of 9.005. This is 58.8% higher than average price of previous purchases of FOLD. |
| CRNX - Crinetics Pharmaceuticals Inc | BUY | 154 @ USD 45.28 | USD 6,973 | The ETF bought 154 new shares of CRNX (Crinetics Pharmaceuticals Inc). The shares were bought for an average price of 45.28 compared to the previous average buy price of 40.4258. This is 12.0% higher than average price of previous purchases of CRNX. |
| CGON - CG Oncology, Inc. Common stock | BUY | 131 @ USD 50.36 | USD 6,597 | The ETF bought 131 new shares of CGON (CG Oncology, Inc. Common stock). The shares were bought for an average price of 50.36 compared to the previous average buy price of 36.1033. This is 39.5% higher than average price of previous purchases of CGON. |
| ACAD - ACADIA Pharmaceuticals Inc | BUY | 275 @ USD 23.56 | USD 6,479 | The ETF bought 275 new shares of ACAD (ACADIA Pharmaceuticals Inc). The shares were bought for an average price of 23.56 compared to the previous average buy price of 22.7248. This is 3.7% higher than average price of previous purchases of ACAD. |
| ACLX - Arcellx Inc | BUY | 94 @ USD 68.03 | USD 6,395 | The ETF bought 94 new shares of ACLX (Arcellx Inc). The shares were bought for an average price of 68.03 compared to the previous average buy price of 71.6095. This is -5.0% lower than average price of previous purchases of ACLX. |
| ADMA - ADMA Biologics Inc | BUY | 386 @ USD 16.43 | USD 6,342 | The ETF bought 386 new shares of ADMA (ADMA Biologics Inc). The shares were bought for an average price of 16.43 compared to the previous average buy price of 17.7683. This is -7.5% lower than average price of previous purchases of ADMA. |
| GRAL - GRAIL, LLC | BUY | 63 @ USD 100.07 | USD 6,304 | The ETF bought 63 new shares of GRAL (GRAIL, LLC). The shares were bought for an average price of 100.07 compared to the previous average buy price of 69.9914. This is 43.0% higher than average price of previous purchases of GRAL. |
| LGND - Ligand Pharmaceuticals Incorporated | BUY | 32 @ USD 190.44 | USD 6,094 | The ETF bought 32 new shares of LGND (Ligand Pharmaceuticals Incorporated). The shares were bought for an average price of 190.44 compared to the previous average buy price of 156.469. This is 21.7% higher than average price of previous purchases of LGND. |
| ERAS - Erasca Inc | BUY | 461 @ USD 12.29 | USD 5,666 | The ETF bought 461 new shares of ERAS (Erasca Inc). The shares were bought for an average price of 12.29 compared to the previous average buy price of 2.98776. This is 311.3% higher than average price of previous purchases of ERAS. |
| APGE - Apogee Therapeutics, Inc. Common Stock | BUY | 89 @ USD 62.24 | USD 5,539 | The ETF bought 89 new shares of APGE (Apogee Therapeutics, Inc. Common Stock). The shares were bought for an average price of 62.24 compared to the previous average buy price of 59.7738. This is 4.1% higher than average price of previous purchases of APGE. |
| TERN - Tern Plc | BUY | 146 @ USD 37.77 | USD 5,514 | The ETF bought 146 new shares of TERN (Tern Plc). The shares were bought for an average price of 37.77 compared to the previous average buy price of 14.8238. This is 154.8% higher than average price of previous purchases of TERN. |
| ARQT - Arcutis Biotherapeutics Inc | BUY | 199 @ USD 27.32 | USD 5,437 | The ETF bought 199 new shares of ARQT (Arcutis Biotherapeutics Inc). The shares were bought for an average price of 27.32 compared to the previous average buy price of 21.2063. This is 28.8% higher than average price of previous purchases of ARQT. |
| XENE - Xenon Pharmaceuticals Inc | BUY | 125 @ USD 41.38 | USD 5,173 | The ETF bought 125 new shares of XENE (Xenon Pharmaceuticals Inc). The shares were bought for an average price of 41.38 compared to the previous average buy price of 38.2163. This is 8.3% higher than average price of previous purchases of XENE. |
| DNLI - Denali Therapeutics Inc | BUY | 238 @ USD 21.08 | USD 5,017 | The ETF bought 238 new shares of DNLI (Denali Therapeutics Inc). The shares were bought for an average price of 21.08 compared to the previous average buy price of 16.5301. This is 27.5% higher than average price of previous purchases of DNLI. |
| EWTX - Edgewise Therapeutics Inc | BUY | 172 @ USD 29.1 | USD 5,005 | The ETF bought 172 new shares of EWTX (Edgewise Therapeutics Inc). The shares were bought for an average price of 29.1 compared to the previous average buy price of 19.2365. This is 51.3% higher than average price of previous purchases of EWTX. |
| TWST - Twist Bioscience Corp | BUY | 99 @ USD 49.24 | USD 4,875 | The ETF bought 99 new shares of TWST (Twist Bioscience Corp). The shares were bought for an average price of 49.24 compared to the previous average buy price of 35.365. This is 39.2% higher than average price of previous purchases of TWST. |
| IRON - Ironveld Plc | BUY | 61 @ USD 79.72 | USD 4,863 | The ETF bought 61 new shares of IRON (Ironveld Plc). The shares were bought for an average price of 79.72 compared to the previous average buy price of 67.509. This is 18.1% higher than average price of previous purchases of IRON. |
| APLS - Apellis Pharmaceuticals Inc | BUY | 205 @ USD 23.49 | USD 4,815 | The ETF bought 205 new shares of APLS (Apellis Pharmaceuticals Inc). The shares were bought for an average price of 23.49 compared to the previous average buy price of 21.2578. This is 10.5% higher than average price of previous purchases of APLS. |
| SUPN - Supernus Pharmaceuticals Inc | BUY | 93 @ USD 51.65 | USD 4,803 | The ETF bought 93 new shares of SUPN (Supernus Pharmaceuticals Inc). The shares were bought for an average price of 51.65 compared to the previous average buy price of 41.1817. This is 25.4% higher than average price of previous purchases of SUPN. |
| VCYT - Veracyte Inc | BUY | 128 @ USD 36.19 | USD 4,632 | The ETF bought 128 new shares of VCYT (Veracyte Inc). The shares were bought for an average price of 36.19 compared to the previous average buy price of 36.1094. This is 0.2% higher than average price of previous purchases of VCYT. |
| IDYA - Ideaya Biosciences Inc | BUY | 142 @ USD 32.17 | USD 4,568 | The ETF bought 142 new shares of IDYA (Ideaya Biosciences Inc). The shares were bought for an average price of 32.17 compared to the previous average buy price of 27.6314. This is 16.4% higher than average price of previous purchases of IDYA. |
| VERA - Vera Therapeutics Inc | BUY | 104 @ USD 43.5 | USD 4,524 | The ETF bought 104 new shares of VERA (Vera Therapeutics Inc). The shares were bought for an average price of 43.5 compared to the previous average buy price of 32.6928. This is 33.1% higher than average price of previous purchases of VERA. |
| TARS - Tarsus Pharmaceuticals Inc | BUY | 69 @ USD 64.62 | USD 4,459 | The ETF bought 69 new shares of TARS (Tarsus Pharmaceuticals Inc). The shares were bought for an average price of 64.62 compared to the previous average buy price of 59.1901. This is 9.2% higher than average price of previous purchases of TARS. |
| SYRE - Spyre Therapeutics Inc. | BUY | 126 @ USD 35.12 | USD 4,425 | The ETF bought 126 new shares of SYRE (Spyre Therapeutics Inc.). The shares were bought for an average price of 35.12 compared to the previous average buy price of 25.7383. This is 36.5% higher than average price of previous purchases of SYRE. |
| BEAM - Beam Therapeutics Inc | BUY | 165 @ USD 26.52 | USD 4,376 | The ETF bought 165 new shares of BEAM (Beam Therapeutics Inc). The shares were bought for an average price of 26.52 compared to the previous average buy price of 23.0751. This is 14.9% higher than average price of previous purchases of BEAM. |
| TVTX - Travere Therapeutics Inc | BUY | 145 @ USD 29.71 | USD 4,308 | The ETF bought 145 new shares of TVTX (Travere Therapeutics Inc). The shares were bought for an average price of 29.71 compared to the previous average buy price of 25.1961. This is 17.9% higher than average price of previous purchases of TVTX. |
| ADPT - Adaptive Biotechnologies Corp | BUY | 248 @ USD 15.77 | USD 3,911 | The ETF bought 248 new shares of ADPT (Adaptive Biotechnologies Corp). The shares were bought for an average price of 15.77 compared to the previous average buy price of 14.0776. This is 12.0% higher than average price of previous purchases of ADPT. |
| DYN - Dyne Therapeutics Inc | BUY | 232 @ USD 16.8 | USD 3,898 | The ETF bought 232 new shares of DYN (Dyne Therapeutics Inc). The shares were bought for an average price of 16.8 compared to the previous average buy price of 15.2584. This is 10.1% higher than average price of previous purchases of DYN. |
| DYN - DYNAGREEN EN.PR.GR.H YC 1 | BUY | 232 @ USD 16.8 | USD 3,898 | The ETF bought 232 new shares of DYN (DYNAGREEN EN.PR.GR.H YC 1). The shares were bought for an average price of 16.8 compared to the previous average buy price of 15.2584. This is 10.1% higher than average price of previous purchases of DYN. |
| RARE - Ultragenyx | BUY | 157 @ USD 24.7 | USD 3,878 | The ETF bought 157 new shares of RARE (Ultragenyx). The shares were bought for an average price of 24.7 compared to the previous average buy price of 34.1094. This is -27.6% lower than average price of previous purchases of RARE. |
| RARE - WISETFWTMRARETFP | BUY | 157 @ USD 24.7 | USD 3,878 | The ETF bought 157 new shares of RARE (WISETFWTMRARETFP). The shares were bought for an average price of 24.7 compared to the previous average buy price of 34.1094. This is -27.6% lower than average price of previous purchases of RARE. |
| MLYS - Mineralys Therapeutics, Inc. Common Stock | BUY | 128 @ USD 29.77 | USD 3,811 | The ETF bought 128 new shares of MLYS (Mineralys Therapeutics, Inc. Common Stock). The shares were bought for an average price of 29.77 compared to the previous average buy price of 27.1807. This is 9.5% higher than average price of previous purchases of MLYS. |
| CNTA - Centessa Pharmaceuticals PLC ADR | BUY | 157 @ USD 23.49 | USD 3,688 | The ETF bought 157 new shares of CNTA (Centessa Pharmaceuticals PLC ADR). The shares were bought for an average price of 23.49 compared to the previous average buy price of 20.0065. This is 17.4% higher than average price of previous purchases of CNTA. |
| WVE - Wave Life Sciences Ltd | BUY | 271 @ USD 13.45 | USD 3,645 | The ETF bought 271 new shares of WVE (Wave Life Sciences Ltd). The shares were bought for an average price of 13.45 compared to the previous average buy price of 9.09755. This is 47.8% higher than average price of previous purchases of WVE. |
| TXG - 10X Genomics Inc | BUY | 189 @ USD 18.61 | USD 3,517 | The ETF bought 189 new shares of TXG (10X Genomics Inc). The shares were bought for an average price of 18.61 compared to the previous average buy price of 14.6276. This is 27.2% higher than average price of previous purchases of TXG. |
| TXG - Terex Corporation | BUY | 189 @ USD 18.61 | USD 3,517 | The ETF bought 189 new shares of TXG (Terex Corporation). The shares were bought for an average price of 18.61 compared to the previous average buy price of 14.6276. This is 27.2% higher than average price of previous purchases of TXG. |
| HRMY - Harmony Biosciences Holdings | BUY | 94 @ USD 37.27 | USD 3,503 | The ETF bought 94 new shares of HRMY (Harmony Biosciences Holdings). The shares were bought for an average price of 37.27 compared to the previous average buy price of 33.8811. This is 10.0% higher than average price of previous purchases of HRMY. |
| RXRX - Recursion Pharmaceuticals Inc | BUY | 834 @ USD 3.98 | USD 3,319 | The ETF bought 834 new shares of RXRX (Recursion Pharmaceuticals Inc). The shares were bought for an average price of 3.98 compared to the previous average buy price of 5.21628. This is -23.7% lower than average price of previous purchases of RXRX. |
| OLMA - Olema Pharmaceuticals Inc | BUY | 128 @ USD 25.36 | USD 3,246 | The ETF bought 128 new shares of OLMA (Olema Pharmaceuticals Inc). The shares were bought for an average price of 25.36 compared to the previous average buy price of 14.6053. This is 73.6% higher than average price of previous purchases of OLMA. |
| OCUL - Ocular Therapeutix Inc | BUY | 346 @ USD 9.16 | USD 3,169 | The ETF bought 346 new shares of OCUL (Ocular Therapeutix Inc). The shares were bought for an average price of 9.16 compared to the previous average buy price of 11.0137. This is -16.8% lower than average price of previous purchases of OCUL. |
| KNSA - Kiniksa Pharmaceuticals Ltd | BUY | 73 @ USD 43.09 | USD 3,146 | The ETF bought 73 new shares of KNSA (Kiniksa Pharmaceuticals Ltd). The shares were bought for an average price of 43.09 compared to the previous average buy price of 34.1119. This is 26.3% higher than average price of previous purchases of KNSA. |
| SRPT - Sarepta Therapeutics Inc | BUY | 170 @ USD 18.5 | USD 3,145 | The ETF bought 170 new shares of SRPT (Sarepta Therapeutics Inc). The shares were bought for an average price of 18.5 compared to the previous average buy price of 29.1858. This is -36.6% lower than average price of previous purchases of SRPT. |
| AUPH - Aurinia Pharmaceuticals Inc | BUY | 214 @ USD 14.44 | USD 3,090 | The ETF bought 214 new shares of AUPH (Aurinia Pharmaceuticals Inc). The shares were bought for an average price of 14.44 compared to the previous average buy price of 11.9401. This is 20.9% higher than average price of previous purchases of AUPH. |
| STOK - Stoke Therapeutics Inc | BUY | 93 @ USD 32.4 | USD 3,013 | The ETF bought 93 new shares of STOK (Stoke Therapeutics Inc). The shares were bought for an average price of 32.4 compared to the previous average buy price of 21.3828. This is 51.5% higher than average price of previous purchases of STOK. |
| VCEL - Vericel Corp Ord | BUY | 82 @ USD 36.19 | USD 2,968 | The ETF bought 82 new shares of VCEL (Vericel Corp Ord). The shares were bought for an average price of 36.19 compared to the previous average buy price of 39.5515. This is -8.5% lower than average price of previous purchases of VCEL. |
| SNDX - Syndax Pharmaceuticals Inc | BUY | 141 @ USD 21.01 | USD 2,962 | The ETF bought 141 new shares of SNDX (Syndax Pharmaceuticals Inc). The shares were bought for an average price of 21.01 compared to the previous average buy price of 15.0835. This is 39.3% higher than average price of previous purchases of SNDX. |
| DVAX - Dynavax Technologies Corporation | BUY | 191 @ USD 15.5 | USD 2,961 | The ETF bought 191 new shares of DVAX (Dynavax Technologies Corporation). The shares were bought for an average price of 15.5 compared to the previous average buy price of 11.4522. This is 35.3% higher than average price of previous purchases of DVAX. |
| ANIP - ANI Pharmaceuticals Inc | BUY | 36 @ USD 81.84 | USD 2,946 | The ETF bought 36 new shares of ANIP (ANI Pharmaceuticals Inc). The shares were bought for an average price of 81.84 compared to the previous average buy price of 76.8679. This is 6.5% higher than average price of previous purchases of ANIP. |
| GMAB - Genmab AS | BUY | 95 @ USD 30.9 | USD 2,936 | The ETF bought 95 new shares of GMAB (Genmab AS). The shares were bought for an average price of 30.9 compared to the previous average buy price of 28.8573. This is 7.1% higher than average price of previous purchases of GMAB. |
| ARDX - Ardelyx Inc | BUY | 395 @ USD 7.32 | USD 2,891 | The ETF bought 395 new shares of ARDX (Ardelyx Inc). The shares were bought for an average price of 7.32 compared to the previous average buy price of 5.23971. This is 39.7% higher than average price of previous purchases of ARDX. |
| MNKD - MannKind Corp | BUY | 499 @ USD 5.78 | USD 2,884 | The ETF bought 499 new shares of MNKD (MannKind Corp). The shares were bought for an average price of 5.78 compared to the previous average buy price of 5.04011. This is 14.7% higher than average price of previous purchases of MNKD. |
| HROW - Harrow Health Inc | BUY | 60 @ USD 47.32 | USD 2,839 | The ETF bought 60 new shares of HROW (Harrow Health Inc). The shares were bought for an average price of 47.32 compared to the previous average buy price of 38.6041. This is 22.6% higher than average price of previous purchases of HROW. |
| ELVN - Enliven Therapeutics Inc. | BUY | 96 @ USD 29.42 | USD 2,824 | The ETF bought 96 new shares of ELVN (Enliven Therapeutics Inc.). The shares were bought for an average price of 29.42 compared to the previous average buy price of 21.7337. This is 35.4% higher than average price of previous purchases of ELVN. |
| NRIX - Nurix Therapeutics Inc | BUY | 165 @ USD 16.85 | USD 2,780 | The ETF bought 165 new shares of NRIX (Nurix Therapeutics Inc). The shares were bought for an average price of 16.85 compared to the previous average buy price of 15.2241. This is 10.7% higher than average price of previous purchases of NRIX. |
| ZYME - Zymeworks Inc. Common Stock | BUY | 122 @ USD 22.72 | USD 2,772 | The ETF bought 122 new shares of ZYME (Zymeworks Inc. Common Stock). The shares were bought for an average price of 22.72 compared to the previous average buy price of 18.372. This is 23.7% higher than average price of previous purchases of ZYME. |
| PHVS - Pharvaris BV | BUY | 104 @ USD 26.42 | USD 2,748 | The ETF bought 104 new shares of PHVS (Pharvaris BV). The shares were bought for an average price of 26.42 compared to the previous average buy price of 25.7773. This is 2.5% higher than average price of previous purchases of PHVS. |
| TNGX - Tango Therapeutics Inc | BUY | 219 @ USD 12.51 | USD 2,740 | The ETF bought 219 new shares of TNGX (Tango Therapeutics Inc). The shares were bought for an average price of 12.51 compared to the previous average buy price of 8.33202. This is 50.1% higher than average price of previous purchases of TNGX. |
| INVA - Innoviva Inc | BUY | 122 @ USD 21.8 | USD 2,660 | The ETF bought 122 new shares of INVA (Innoviva Inc). The shares were bought for an average price of 21.8 compared to the previous average buy price of 19.6709. This is 10.8% higher than average price of previous purchases of INVA. |
| RAPT - RAPT Therapeutics Inc | BUY | 46 @ USD 57.69 | USD 2,654 | The ETF bought 46 new shares of RAPT (RAPT Therapeutics Inc). The shares were bought for an average price of 57.69 compared to the previous average buy price of 37.918. This is 52.1% higher than average price of previous purchases of RAPT. |
| QURE - Uniqure NV | BUY | 102 @ USD 25.65 | USD 2,616 | The ETF bought 102 new shares of QURE (Uniqure NV). The shares were bought for an average price of 25.65 compared to the previous average buy price of 23.6023. This is 8.7% higher than average price of previous purchases of QURE. |
| RLAY - Relay Therapeutics Inc | BUY | 283 @ USD 8.92 | USD 2,524 | The ETF bought 283 new shares of RLAY (Relay Therapeutics Inc). The shares were bought for an average price of 8.92 compared to the previous average buy price of 5.27671. This is 69.0% higher than average price of previous purchases of RLAY. |
| AGIO - Agios Pharm | BUY | 95 @ USD 26.53 | USD 2,520 | The ETF bought 95 new shares of AGIO (Agios Pharm). The shares were bought for an average price of 26.53 compared to the previous average buy price of 32.99. This is -19.6% lower than average price of previous purchases of AGIO. |
| AMLX - Amylyx Pharmaceuticals Inc | BUY | 178 @ USD 13.98 | USD 2,488 | The ETF bought 178 new shares of AMLX (Amylyx Pharmaceuticals Inc). The shares were bought for an average price of 13.98 compared to the previous average buy price of 9.72743. This is 43.7% higher than average price of previous purchases of AMLX. |
| PGEN - Precigen Inc | BUY | 573 @ USD 4.29 | USD 2,458 | The ETF bought 573 new shares of PGEN (Precigen Inc). The shares were bought for an average price of 4.29 compared to the previous average buy price of 3.20851. This is 33.7% higher than average price of previous purchases of PGEN. |
| COLL - Collegium Pharmaceutical Inc | BUY | 51 @ USD 47.61 | USD 2,428 | The ETF bought 51 new shares of COLL (Collegium Pharmaceutical Inc). The shares were bought for an average price of 47.61 compared to the previous average buy price of 37.3128. This is 27.6% higher than average price of previous purchases of COLL. |
| LEGN - Legend Biotech Corp | BUY | 137 @ USD 17.1 | USD 2,343 | The ETF bought 137 new shares of LEGN (Legend Biotech Corp). The shares were bought for an average price of 17.1 compared to the previous average buy price of 30.8737. This is -44.6% lower than average price of previous purchases of LEGN. |
| NTLA - Intellia Therapeutics Inc | BUY | 188 @ USD 12.28 | USD 2,309 | The ETF bought 188 new shares of NTLA (Intellia Therapeutics Inc). The shares were bought for an average price of 12.28 compared to the previous average buy price of 11.5896. This is 6.0% higher than average price of previous purchases of NTLA. |
| IMCR - Immunocore Holdings Ltd | BUY | 71 @ USD 31.98 | USD 2,271 | The ETF bought 71 new shares of IMCR (Immunocore Holdings Ltd). The shares were bought for an average price of 31.98 compared to the previous average buy price of 34.1772. This is -6.4% lower than average price of previous purchases of IMCR. |
| ANAB - AnaptysBio Inc | BUY | 45 @ USD 49.73 | USD 2,238 | The ETF bought 45 new shares of ANAB (AnaptysBio Inc). The shares were bought for an average price of 49.73 compared to the previous average buy price of 31.2589. This is 59.1% higher than average price of previous purchases of ANAB. |
| FTRE - Fortrea Holdings Inc. | BUY | 150 @ USD 14.65 | USD 2,198 | The ETF bought 150 new shares of FTRE (Fortrea Holdings Inc.). The shares were bought for an average price of 14.65 compared to the previous average buy price of 9.81945. This is 49.2% higher than average price of previous purchases of FTRE. |
| AMPH - Amphastar P | BUY | 75 @ USD 29.26 | USD 2,195 | The ETF bought 75 new shares of AMPH (Amphastar P). The shares were bought for an average price of 29.26 compared to the previous average buy price of 26.0369. This is 12.4% higher than average price of previous purchases of AMPH. |
| BCRX - BioCryst Pharmaceuticals Inc | BUY | 343 @ USD 6.38 | USD 2,188 | The ETF bought 343 new shares of BCRX (BioCryst Pharmaceuticals Inc). The shares were bought for an average price of 6.38 compared to the previous average buy price of 7.87306. This is -19.0% lower than average price of previous purchases of BCRX. |
| NVAX - Novavax Inc | BUY | 265 @ USD 8.25 | USD 2,186 | The ETF bought 265 new shares of NVAX (Novavax Inc). The shares were bought for an average price of 8.25 compared to the previous average buy price of 7.35783. This is 12.1% higher than average price of previous purchases of NVAX. |
| NVAX - Hana Microelectronics Public Company Limited | BUY | 265 @ USD 8.25 | USD 2,186 | The ETF bought 265 new shares of NVAX (Hana Microelectronics Public Company Limited). The shares were bought for an average price of 8.25 compared to the previous average buy price of 7.35783. This is 12.1% higher than average price of previous purchases of NVAX. |
| TSHA - Taysha Gene Therapies Inc | BUY | 446 @ USD 4.61 | USD 2,056 | The ETF bought 446 new shares of TSHA (Taysha Gene Therapies Inc). The shares were bought for an average price of 4.61 compared to the previous average buy price of 3.47806. This is 32.5% higher than average price of previous purchases of TSHA. |
| XERS - Xeris Pharmaceuticals Inc | BUY | 272 @ USD 7.01 | USD 1,907 | The ETF bought 272 new shares of XERS (Xeris Pharmaceuticals Inc). The shares were bought for an average price of 7.01 compared to the previous average buy price of 6.43524. This is 8.9% higher than average price of previous purchases of XERS. |
| DAWN - Day One Biopharmaceuticals Inc | BUY | 167 @ USD 11.41 | USD 1,905 | The ETF bought 167 new shares of DAWN (Day One Biopharmaceuticals Inc). The shares were bought for an average price of 11.41 compared to the previous average buy price of 8.18228. This is 39.4% higher than average price of previous purchases of DAWN. |
| GRFS - Grifols SA ADR | BUY | 201 @ USD 9.28001 | USD 1,865 | The ETF bought 201 new shares of GRFS (Grifols SA ADR). The shares were bought for an average price of 9.28001 compared to the previous average buy price of 9.14725. This is 1.5% higher than average price of previous purchases of GRFS. |
| NVCR - Novocure Ltd | BUY | 182 @ USD 10.14 | USD 1,845 | The ETF bought 182 new shares of NVCR (Novocure Ltd). The shares were bought for an average price of 10.14 compared to the previous average buy price of 15.1761. This is -33.2% lower than average price of previous purchases of NVCR. |
| SVRA - Savara Inc | BUY | 333 @ USD 5.3 | USD 1,765 | The ETF bought 333 new shares of SVRA (Savara Inc). The shares were bought for an average price of 5.3 compared to the previous average buy price of 4.52806. This is 17.0% higher than average price of previous purchases of SVRA. |
| PAHC - Phibro Animal Health Corporation | BUY | 33 @ USD 53.07 | USD 1,751 | The ETF bought 33 new shares of PAHC (Phibro Animal Health Corporation). The shares were bought for an average price of 53.07 compared to the previous average buy price of 32.1199. This is 65.2% higher than average price of previous purchases of PAHC. |
| SANA - Sana Biotechnology Inc | BUY | 433 @ USD 3.93 | USD 1,702 | The ETF bought 433 new shares of SANA (Sana Biotechnology Inc). The shares were bought for an average price of 3.93 compared to the previous average buy price of 3.67015. This is 7.1% higher than average price of previous purchases of SANA. |
| TBPH - Theravance Biopharma Inc | BUY | 83 @ USD 20.48 | USD 1,700 | The ETF bought 83 new shares of TBPH (Theravance Biopharma Inc). The shares were bought for an average price of 20.48 compared to the previous average buy price of 14.7061. This is 39.3% higher than average price of previous purchases of TBPH. |
| VTYX - Ventyx Biosciences Inc | BUY | 119 @ USD 13.96 | USD 1,661 | The ETF bought 119 new shares of VTYX (Ventyx Biosciences Inc). The shares were bought for an average price of 13.96 compared to the previous average buy price of 13.6812. This is 2.0% higher than average price of previous purchases of VTYX. |
| ORIC - Oric Pharmaceuticals Inc | BUY | 158 @ USD 10.42 | USD 1,646 | The ETF bought 158 new shares of ORIC (Oric Pharmaceuticals Inc). The shares were bought for an average price of 10.42 compared to the previous average buy price of 10.8434. This is -3.9% lower than average price of previous purchases of ORIC. |
| SPRY - Silverback Therapeutics Inc | BUY | 163 @ USD 10.03 | USD 1,635 | The ETF bought 163 new shares of SPRY (Silverback Therapeutics Inc). The shares were bought for an average price of 10.03 compared to the previous average buy price of 12.089. This is -17.0% lower than average price of previous purchases of SPRY. |
| VIR - Vir Biotechnology Inc | BUY | 227 @ USD 7.19 | USD 1,632 | The ETF bought 227 new shares of VIR (Vir Biotechnology Inc). The shares were bought for an average price of 7.19 compared to the previous average buy price of 5.99932. This is 19.8% higher than average price of previous purchases of VIR. |
| VIR - Vidrala S.A | BUY | 227 @ USD 7.19 | USD 1,632 | The ETF bought 227 new shares of VIR (Vidrala S.A). The shares were bought for an average price of 7.19 compared to the previous average buy price of 5.99932. This is 19.8% higher than average price of previous purchases of VIR. |
| IOVA - Iovance Biotherapeutics Inc | BUY | 644 @ USD 2.53 | USD 1,629 | The ETF bought 644 new shares of IOVA (Iovance Biotherapeutics Inc). The shares were bought for an average price of 2.53 compared to the previous average buy price of 2.39882. This is 5.5% higher than average price of previous purchases of IOVA. |
| GERN - Geron Corporation | BUY | 1,047 @ USD 1.53 | USD 1,602 | The ETF bought 1047 new shares of GERN (Geron Corporation). The shares were bought for an average price of 1.53 compared to the previous average buy price of 1.42386. This is 7.5% higher than average price of previous purchases of GERN. |
| CSTL - Castle Biosciences Inc | BUY | 48 @ USD 32.75 | USD 1,572 | The ETF bought 48 new shares of CSTL (Castle Biosciences Inc). The shares were bought for an average price of 32.75 compared to the previous average buy price of 28.8317. This is 13.6% higher than average price of previous purchases of CSTL. |
| URGN - UroGen Pharma Ltd | BUY | 73 @ USD 21.35 | USD 1,559 | The ETF bought 73 new shares of URGN (UroGen Pharma Ltd). The shares were bought for an average price of 21.35 compared to the previous average buy price of 17.2681. This is 23.6% higher than average price of previous purchases of URGN. |
| ABCL - Abcellera Biologics Inc | BUY | 486 @ USD 3.16 | USD 1,536 | The ETF bought 486 new shares of ABCL (Abcellera Biologics Inc). The shares were bought for an average price of 3.16 compared to the previous average buy price of 3.87245. This is -18.4% lower than average price of previous purchases of ABCL. |
| PCRX - Pacira BioSciences, Inc. | BUY | 72 @ USD 21 | USD 1,512 | The ETF bought 72 new shares of PCRX (Pacira BioSciences, Inc.). The shares were bought for an average price of 21 compared to the previous average buy price of 23.2839. This is -9.8% lower than average price of previous purchases of PCRX. |
| PHAT - Phathom Pharmaceuticals Inc | BUY | 118 @ USD 12.58 | USD 1,484 | The ETF bought 118 new shares of PHAT (Phathom Pharmaceuticals Inc). The shares were bought for an average price of 12.58 compared to the previous average buy price of 11.2727. This is 11.6% higher than average price of previous purchases of PHAT. |
| XNCR - Xencor Inc | BUY | 118 @ USD 11.61 | USD 1,370 | The ETF bought 118 new shares of XNCR (Xencor Inc). The shares were bought for an average price of 11.61 compared to the previous average buy price of 12.7111. This is -8.7% lower than average price of previous purchases of XNCR. |
| ARVN - Arvinas Inc | BUY | 100 @ USD 13.48 | USD 1,348 | The ETF bought 100 new shares of ARVN (Arvinas Inc). The shares were bought for an average price of 13.48 compared to the previous average buy price of 10.1192. This is 33.2% higher than average price of previous purchases of ARVN. |
| JANX - Janux Therapeutics Inc | BUY | 99 @ USD 13.07 | USD 1,294 | The ETF bought 99 new shares of JANX (Janux Therapeutics Inc). The shares were bought for an average price of 13.07 compared to the previous average buy price of 24.1185. This is -45.8% lower than average price of previous purchases of JANX. |
| KALV - Kalvista Pharmaceuticals Inc | BUY | 86 @ USD 14.9 | USD 1,281 | The ETF bought 86 new shares of KALV (Kalvista Pharmaceuticals Inc). The shares were bought for an average price of 14.9 compared to the previous average buy price of 13.8064. This is 7.9% higher than average price of previous purchases of KALV. |
| ABUS - Arbutus Biopharma Corp | BUY | 320 @ USD 3.84 | USD 1,229 | The ETF bought 320 new shares of ABUS (Arbutus Biopharma Corp). The shares were bought for an average price of 3.84 compared to the previous average buy price of 3.9277. This is -2.2% lower than average price of previous purchases of ABUS. |
| CGEM - Cullinan Oncology LLC | BUY | 100 @ USD 12.23 | USD 1,223 | The ETF bought 100 new shares of CGEM (Cullinan Oncology LLC). The shares were bought for an average price of 12.23 compared to the previous average buy price of 9.1155. This is 34.2% higher than average price of previous purchases of CGEM. |
| KURA - Kura Oncology Inc | BUY | 147 @ USD 7.83 | USD 1,151 | The ETF bought 147 new shares of KURA (Kura Oncology Inc). The shares were bought for an average price of 7.83 compared to the previous average buy price of 8.39705. This is -6.8% lower than average price of previous purchases of KURA. |
| IRWD - Ironwood Pharmaceuticals Inc | BUY | 252 @ USD 4.56 | USD 1,149 | The ETF bought 252 new shares of IRWD (Ironwood Pharmaceuticals Inc). The shares were bought for an average price of 4.56 compared to the previous average buy price of 2.54624. This is 79.1% higher than average price of previous purchases of IRWD. |
| ZLAB - Zai Lab Ltd | BUY | 61 @ USD 18 | USD 1,098 | The ETF bought 61 new shares of ZLAB (Zai Lab Ltd). The shares were bought for an average price of 18 compared to the previous average buy price of 30.2779. This is -40.6% lower than average price of previous purchases of ZLAB. |
| PRME - Prime Medicine, Inc. Common Stock | BUY | 288 @ USD 3.57 | USD 1,028 | The ETF bought 288 new shares of PRME (Prime Medicine, Inc. Common Stock). The shares were bought for an average price of 3.57 compared to the previous average buy price of 3.89249. This is -8.3% lower than average price of previous purchases of PRME. |
| MGTX - MeiraGTx Holdings PLC | BUY | 135 @ USD 7.43 | USD 1,003 | The ETF bought 135 new shares of MGTX (MeiraGTx Holdings PLC). The shares were bought for an average price of 7.43 compared to the previous average buy price of 7.43649. This is -0.1% lower than average price of previous purchases of MGTX. |
| REPL - Replimune Group Inc | BUY | 120 @ USD 7.75001 | USD 930 | The ETF bought 120 new shares of REPL (Replimune Group Inc). The shares were bought for an average price of 7.75001 compared to the previous average buy price of 9.11352. This is -15.0% lower than average price of previous purchases of REPL. |
| RGNX - Regenxbio Inc | BUY | 86 @ USD 10.33 | USD 888 | The ETF bought 86 new shares of RGNX (Regenxbio Inc). The shares were bought for an average price of 10.33 compared to the previous average buy price of 10.792. This is -4.3% lower than average price of previous purchases of RGNX. |
| FDMT - 4D Molecular Therapeutics Inc | BUY | 95 @ USD 8.98999 | USD 854 | The ETF bought 95 new shares of FDMT (4D Molecular Therapeutics Inc). The shares were bought for an average price of 8.98999 compared to the previous average buy price of 7.79169. This is 15.4% higher than average price of previous purchases of FDMT. |
| PACB - Pacific Biosciences of California | BUY | 468 @ USD 1.82 | USD 852 | The ETF bought 468 new shares of PACB (Pacific Biosciences of California). The shares were bought for an average price of 1.82 compared to the previous average buy price of 1.76258. This is 3.3% higher than average price of previous purchases of PACB. |
| KROS - Keros Therapeutics Inc | BUY | 47 @ USD 17.57 | USD 826 | The ETF bought 47 new shares of KROS (Keros Therapeutics Inc). The shares were bought for an average price of 17.57 compared to the previous average buy price of 16.0487. This is 9.5% higher than average price of previous purchases of KROS. |
| FULC - Fulcrum Therapeutics Inc | BUY | 84 @ USD 9.73999 | USD 818 | The ETF bought 84 new shares of FULC (Fulcrum Therapeutics Inc). The shares were bought for an average price of 9.73999 compared to the previous average buy price of 10.4062. This is -6.4% lower than average price of previous purchases of FULC. |
| LYEL - Lyell Immunopharma Inc | BUY | 36 @ USD 22.71 | USD 818 | The ETF bought 36 new shares of LYEL (Lyell Immunopharma Inc). The shares were bought for an average price of 22.71 compared to the previous average buy price of 10.2645. This is 121.2% higher than average price of previous purchases of LYEL. |
| PRTA - Prothena Corporation plc | BUY | 91 @ USD 8.90999 | USD 811 | The ETF bought 91 new shares of PRTA (Prothena Corporation plc). The shares were bought for an average price of 8.90999 compared to the previous average buy price of 9.49892. This is -6.2% lower than average price of previous purchases of PRTA. |
| ALT - Altitude Group Plc | BUY | 161 @ USD 4.87 | USD 784 | The ETF bought 161 new shares of ALT (Altitude Group Plc). The shares were bought for an average price of 4.87 compared to the previous average buy price of 4.88961. This is -0.4% lower than average price of previous purchases of ALT. |
| SIGA - SIGA Technologies Inc | BUY | 115 @ USD 6.70001 | USD 771 | The ETF bought 115 new shares of SIGA (SIGA Technologies Inc). The shares were bought for an average price of 6.70001 compared to the previous average buy price of 6.63011. This is 1.1% higher than average price of previous purchases of SIGA. |
| GLPG - Galapagos NV ADR | BUY | 22 @ USD 33.36 | USD 734 | The ETF bought 22 new shares of GLPG (Galapagos NV ADR). The shares were bought for an average price of 33.36 compared to the previous average buy price of 29.9762. This is 11.3% higher than average price of previous purchases of GLPG. |
| GLPG - Galapagos N.V. | BUY | 22 @ USD 33.36 | USD 734 | The ETF bought 22 new shares of GLPG (Galapagos N.V.). The shares were bought for an average price of 33.36 compared to the previous average buy price of 29.9762. This is 11.3% higher than average price of previous purchases of GLPG. |
| MRVI - Maravai Lifesciences Holdings Inc | BUY | 225 @ USD 3.14 | USD 707 | The ETF bought 225 new shares of MRVI (Maravai Lifesciences Holdings Inc). The shares were bought for an average price of 3.14 compared to the previous average buy price of 3.0025. This is 4.6% higher than average price of previous purchases of MRVI. |
| VNDA - Vanda Pharmaceuticals Inc | BUY | 91 @ USD 7.57 | USD 689 | The ETF bought 91 new shares of VNDA (Vanda Pharmaceuticals Inc). The shares were bought for an average price of 7.57 compared to the previous average buy price of 5.12938. This is 47.6% higher than average price of previous purchases of VNDA. |
| TRDA - Entrada Therapeutics Inc | BUY | 59 @ USD 10.6 | USD 625 | The ETF bought 59 new shares of TRDA (Entrada Therapeutics Inc). The shares were bought for an average price of 10.6 compared to the previous average buy price of 8.45157. This is 25.4% higher than average price of previous purchases of TRDA. |
| ALLO - Allogene Therapeutics Inc | BUY | 360 @ USD 1.69 | USD 608 | The ETF bought 360 new shares of ALLO (Allogene Therapeutics Inc). The shares were bought for an average price of 1.69 compared to the previous average buy price of 1.37379. This is 23.0% higher than average price of previous purchases of ALLO. |
| ACRS - Aclaris Therapeutics Inc | BUY | 168 @ USD 3.57 | USD 600 | The ETF bought 168 new shares of ACRS (Aclaris Therapeutics Inc). The shares were bought for an average price of 3.57 compared to the previous average buy price of 3.14453. This is 13.5% higher than average price of previous purchases of ACRS. |
| AVXL - Anavex Life Sciences Corp | BUY | 141 @ USD 4.1 | USD 578 | The ETF bought 141 new shares of AVXL (Anavex Life Sciences Corp). The shares were bought for an average price of 4.1 compared to the previous average buy price of 7.71723. This is -46.9% lower than average price of previous purchases of AVXL. |
| AVIR - Atea Pharmaceuticals Inc | BUY | 138 @ USD 4.15 | USD 573 | The ETF bought 138 new shares of AVIR (Atea Pharmaceuticals Inc). The shares were bought for an average price of 4.15 compared to the previous average buy price of 3.28339. This is 26.4% higher than average price of previous purchases of AVIR. |
| RCKT - Rocket Pharmaceuticals Inc | BUY | 176 @ USD 3.16 | USD 556 | The ETF bought 176 new shares of RCKT (Rocket Pharmaceuticals Inc). The shares were bought for an average price of 3.16 compared to the previous average buy price of 4.60203. This is -31.3% lower than average price of previous purchases of RCKT. |
| ACIU - AC Immune Ltd | BUY | 165 @ USD 3.14001 | USD 518 | The ETF bought 165 new shares of ACIU (AC Immune Ltd). The shares were bought for an average price of 3.14001 compared to the previous average buy price of 2.67561. This is 17.4% higher than average price of previous purchases of ACIU. |
| EOLS - Evolus Inc | BUY | 100 @ USD 4.50001 | USD 450 | The ETF bought 100 new shares of EOLS (Evolus Inc). The shares were bought for an average price of 4.50001 compared to the previous average buy price of 8.32252. This is -45.9% lower than average price of previous purchases of EOLS. |
| BCYC - Bicycle Therapeutics Ltd | BUY | 77 @ USD 5.66 | USD 436 | The ETF bought 77 new shares of BCYC (Bicycle Therapeutics Ltd). The shares were bought for an average price of 5.66 compared to the previous average buy price of 8.03706. This is -29.6% lower than average price of previous purchases of BCYC. |
| AUTL - Autolus Therapeutics Ltd | BUY | 290 @ USD 1.42 | USD 412 | The ETF bought 290 new shares of AUTL (Autolus Therapeutics Ltd). The shares were bought for an average price of 1.42 compared to the previous average buy price of 1.71776. This is -17.3% lower than average price of previous purchases of AUTL. |
| CABA - Cabaletta Bio Inc | BUY | 149 @ USD 2.50999 | USD 374 | The ETF bought 149 new shares of CABA (Cabaletta Bio Inc). The shares were bought for an average price of 2.50999 compared to the previous average buy price of 2.40536. This is 4.3% higher than average price of previous purchases of CABA. |
| ARCT - Arcturus Therapeutics Holdings Inc | BUY | 47 @ USD 7.56999 | USD 356 | The ETF bought 47 new shares of ARCT (Arcturus Therapeutics Holdings Inc). The shares were bought for an average price of 7.56999 compared to the previous average buy price of 12.0564. This is -37.2% lower than average price of previous purchases of ARCT. |
| OABI - OmniAb Inc. | BUY | 203 @ USD 1.7 | USD 345 | The ETF bought 203 new shares of OABI (OmniAb Inc.). The shares were bought for an average price of 1.7 compared to the previous average buy price of 1.88717. This is -9.9% lower than average price of previous purchases of OABI. |
| VYGR - Voyager Therapeutics Inc | BUY | 84 @ USD 3.67999 | USD 309 | The ETF bought 84 new shares of VYGR (Voyager Therapeutics Inc). The shares were bought for an average price of 3.67999 compared to the previous average buy price of 3.95174. This is -6.9% lower than average price of previous purchases of VYGR. |
| EDIT - Editas Medicine Inc | BUY | 157 @ USD 1.82 | USD 286 | The ETF bought 157 new shares of EDIT (Editas Medicine Inc). The shares were bought for an average price of 1.82 compared to the previous average buy price of 2.56093. This is -28.9% lower than average price of previous purchases of EDIT. |
| HUMA - Humacyte Inc | BUY | 265 @ USD 0.938301 | USD 249 | The ETF bought 265 new shares of HUMA (Humacyte Inc). The shares were bought for an average price of 0.938301 compared to the previous average buy price of 1.91297. This is -51.0% lower than average price of previous purchases of HUMA. |
| CRBU - Caribou Biosciences Inc | BUY | 142 @ USD 1.56999 | USD 223 | The ETF bought 142 new shares of CRBU (Caribou Biosciences Inc). The shares were bought for an average price of 1.56999 compared to the previous average buy price of 1.62909. This is -3.6% lower than average price of previous purchases of CRBU. |
| - - | HOLD | 0 @ USD 0 | USD 0 | |
| THRD - Third Harmonic Bio Inc. | HOLD | 0 @ USD 0.0300173 | USD 0 | The current share valuation price of THRD based on adjusted close was USD 0.0300173. The average price that THRD shares were previous bought at was USD 5.04749. The current market price is -99.4% lower than average price they were purchased at. USD 0 compared to the previous valuation of Third Harmonic Bio Inc. however if the holding was sold on 2026-02-06 this would crystalise an overall loss. |